Буденофальк® в клинической практике

Литература
16
Исследования по Буденофальку ®
1. Möllmann HW, Barth J, Hochhaus G, et al.
Principles of topical versus systemic corticosteroid
treatment in inflammatory bowel disease.
Kluwer Academic Publishers, Dordrecht, 42–60 (1996).
3. Bar-Meir S, Chowers Y, Lavy A, et al.
Budesonide versus prednisone in the treatment of active
Crohn‘s disease.
Gastroenterology. 1998;115(4):835–40.
6. Miehlke S, Madisch A, Karimi D, et al.
Budesonide is effective in treating lymphocytic colitis:
a randomized double-blind placebo-controlled study.
Gastroenterology. 2009;136(7):2092–2100
8. Elsing C, Placke J, Gross-Wege W.
Budesonide for the treatment of obstructive eosinophilic
jejunitis.
Z Gastroenterol. 2007;45(2):187–9.
9. Siewert E, Lammert F, Koppitz P, et al.
Eosinophilic gastroenteritis with severe protein-losing
enteropathy: Successful treatment with budesonide.
Dig Liver Dis. 2006;38(1):55–9.
10. Leuschner M, Maier KP, Schlichting J, et al.
Oral budesonide and ursodeoxycholic acid for treatment
of primary biliary cirrhosis: results of a prospective
double-blind trial.
Gastroenterology. 1999;117(4):918–25.
11. Manns MP, Bahr MJ, Woynarowski M, et al.
Budesonide 3 mg TID is superior to prednisone in
combination with azathioprine in the treatment of
autoimmune hepatitis.
J Hepatol. 2008;48 (Suppl.2): S369–S370.
17. Bar-Meir S, Fidder HH, Faszczyk M, et al.
Budesonide foam vs. hydrocortisone acetate foam in the
treatment of active ulcerative proctosigmoiditis.
Dis Colon Rectum. 2003;46(7):929–36.
18. Gross V, Bar-Meir S, Lavy A, et al.
Budesonide foam versus budesonide enema in active
ulcerative proctitis and proctosigmoiditis.
Aliment Pharmacol Ther. 2006;23(2):303–12.
19. Tromm A, Griga T, Möllmann HW, et al.
Budesonide for the treatment of collagenous colitis:
First results of a pilot trial.
Am J Gastroenterol. 1999;94(7):1871–5.
20. Hammond A, Andus T, Gierend M, et al.
Controlled, open, randomized multicenter trial comparing
the effects of treatment on quality of life, safety and
efficacy of budesonide foam and betamethasone enemas in
patients with active distal ulcerative colitis.
Hepatogastroenterology. 2004;51(59):1345–9.
22. Wiegand J, Schüler A, Kanzler S, et al.
Budesonide in previously untreated autoimmune hepatitis.
Liver Int. 2005;25:927–934.
23. Csepregi A, Röcken C, Treiber G, Malfertheiner P.
Budesonide induces complete remission in autoimmune
hepatitis.
World J Gastroenterol. 2006;12(9):1362–6.
24. Keller R, Stoll R, Foerster EC, et al.
Oral budesonide therapy for steroid-dependent ulcerative
colitis: a pilot trial.
Aliment Pharmacol Ther. 1997;11:1047–52.
25. Kolkman JJ, Möllmann HW, Möllmann AC, et al.
Evaluation of oral budesonide in the treatment of active
distal ulcerative colitis.
Drugs Today. 2004;40:589–601.
26. Ситкин С.И., Жигалова Т.Н., Ткаченко Е.И.
Применение топических кортикостероидов при
болезни Крона и язвенном колите //
Гастроэнтерология Санкт-Петербурга. –
2008. – № 4. – С. 2–6.
27. Ситкин С.И.
Топические кортикостероиды в терапии
воспалительных заболеваний кишечника //
Фарматека. – 2008. – № 13 (167). – С. 84–89.
Дополнительная литература
2. Rutgeerts P, Löfberg R, Malchow H, et al.
A comparison of budesonide with prednisolone
for active Crohn‘s disease.
N Engl J Med. 1994;331(13):842–5.
4. Hochhaus G, Derendorf H, Möllmann HW, et al.
Pharmacodynamic aspects of glucocorticoid action.
Kluwer Academic Publishers, Dordrecht, 61–79 (1996).
5. Kane SV, Schoenfeld P, Sandborn WJ, et al.
The effectiveness of budesonide therapy for Crohn‘s
disease.
Aliment Pharmacol Ther. 2002;16(8):1509–17.
7. Brar P, Lee S, Lewis S, et al.
Budesonide in the treatment of refractory celiac disease.
Am J Gastroenterol. 2007;102(10):2265–9.
12. Stange EF, Schreiber S, Fölsch UR, et al.
[Diagnostics and treatment of Crohn‘s disease – Results of
an evidence-based consensus conference of the German
Society for Digestive and Metabolic Diseases.]
Z Gastroenterol. 2003;41(1):19–20.
13. Travis SPL, Stange EF, Lémann M, et al.
European evidence based consensus on the diagnosis and
management of Crohn‘s disease: current management.
Gut. 2006;55(Suppl 1):i16–i35.
14. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W.
American Gastroenterological Association Institute medical
position statement on corticosteroids, immunomodulators,
and infliximab in inflammatory bowel disease.
Gastroenterology. 2006;130(3):935–9.
15. Otley A, Steinhart AH
Budesonide for induction of remission in Crohn‘s disease.
Cochrane Database Syst Rev. 2005; (4):CD000296.
16. Hoffmann JC, Zeitz M, Bischoff SC, et al.
[Diagnosis and therapy of ulcerative colitis: Results of an
evidence-based consensus conference of the German
Society of Digestive and Metabolic Diseases and the
Competence Network on Inflammatory Bowel Diseases.]
Z Gastroenterol. 2004;42:979–1042.
21. Rautiainen H, Kärkkäinen P, Karvonen AL, et al.
Budesonide combined with UDCA to improve liver
histology in primary biliary cirrhosis: A three-year
randomized trial.
Hepatology. 2005;41:747–52.